Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Aardvark Therapeutics (AARD) faces a newly filed class action lawsuit alleging federal securities law violations tied to its Feb. 13, 2025 IPO and securities purchases during the Feb. 13, 2025–May 14, 2026 class period. The claim seeks to recover damages for investors who bought or acquired shares under the IPO registration statement/prospectus and throughout the class period. While no financial impact is quantified, litigation risk is a potential overhang for the stock.

Analysis

For a small, pre-maturity biotech, the material damage from this kind of litigation is rarely the claim itself; it is the higher discount rate it imposes on any future capital raise. If AARD needs equity within the next 6-12 months, the overhang can translate into a wider follow-on discount, weaker demand from crossover buyers, and a faster path to dilution than peers with cleaner records. That makes the stock especially vulnerable to a second leg down if management has to fund operations before the legal cloud clears.

The more important second-order effect is positioning. Event-driven shorts and retail longs typically coexist in these names, so headline-driven spikes can be sold into, while liquidity remains thin enough that incremental selling can gap the tape. In biotech baskets, this also creates relative value opportunity: capital tends to rotate toward better-governed, better-funded names in XBI/IBB, not away from the asset class entirely. In other words, the underperformer may be AARD specifically, not the whole group.

Contrarian view: these cases are often boilerplate, and if AARD has a long cash runway, insurance coverage, and no follow-on financing need, the fundamental impairment may be close to zero. The move is likely overdone if the stock trades below cash-adjusted value and there is no SEC follow-on, amended complaint, or disclosure shock. The thesis is falsified by a clean dismissal, no financing pressure through the next two reporting cycles, or a management update that meaningfully extends runway without dilution.

Key Decisions for Investors

• Avoid adding to AARD until there is visibility on cash runway and litigation scope; this is a capital-cost problem more than a liability problem. Reassess only if management can show >12-18 months of funding with no follow-on raise.
• If borrow and liquidity are workable, consider a small tactical short on post-headline strength in AARD for a 1-3 month trade. Risk/reward favors fading relief rallies unless the company quickly discloses insurance coverage, dismissal likelihood, or ample liquidity.
• Pair trade: short AARD / long XBI as an idiosyncratic governance-and-financing overhang hedge. This isolates company-specific multiple compression while limiting beta risk if biotech sentiment improves.
• Set alerts for any SEC inquiry, amended complaint, or equity financing filing. Those are the real catalysts that would extend the drawdown and justify adding to the short; absent them, the headline may fade within days.
• If AARD trades to a deep cash-discounted valuation without a financing need, cover shorts aggressively. In that scenario, the market is likely overstating litigation economics relative to actual balance-sheet risk.